Ropes & Gray Represents EQRx in Strategic Collaboration with Insilico Medicine
Ropes & Gray advised EQRx in a strategic collaboration with Insilico Medicine to jointly advance artificial intelligence-driven drug discovery, development and commercialization of multiple disease targets. The deal was announced on March 24.
Under the agreement, the parties will identify and select up to three therapeutics targets leveraging Insilico's AI-driven platform. Insilico will lead drug discovery from small molecule identification through preclinical candidate nomination to IND-filing. EQRx will assume responsibility for driving clinical development, regulatory activities and commercialization.
The Ropes & Gray team was led by life sciences partner Abigail Gregor and associate Kat Kulzer (both of Boston).